ITCI

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Dollar change -0.01
Percentage change -0.01	%

Peers: LLY REGN GILD VRTX INCY BIIB NBIX BMRN ACAD ALKS

| Held by: VTI VB VXF VBK IWP IBB SCHA FBT IWF IWR

Index	-	P/E	-	EPS (ttm)	-0.72	Insider Own	6.94%	Shs Outstand	106.24M	Perf Week	-0.01%
Market Cap	13.95B	Forward P/E	30.91	EPS next Y	4.25	Insider Trans	-1.92%	Shs Float	98.94M	Perf Month	2.89%
Income	-74.68M	PEG	-	EPS next Q	-0.09	Inst Own	83.00%	Short Float	2.36%	Perf Quarter	54.48%
Sales	680.85M	P/S	20.50	EPS this Y	191.46%	Inst Trans	1.77%	Short Ratio	0.76	Perf Half Y	78.42%
Book/sh	10.81	P/B	12.14	EPS next Y	544.86%	ROA	-7.13%	Short Interest	2.33M	Perf Year	100.58%
Cash/sh	9.43	P/C	13.92	EPS next 5Y	-	ROE	-8.58%	52W Range	63.30 - 131.37	Perf YTD	57.14%
Dividend Est.	-	P/FCF	-	EPS past 5Y	23.01%	ROI	-6.43%	52W High	-0.10%	Beta	0.46
Dividend TTM	-	Quick Ratio	6.23	Sales past 5Y	7627.06%	Gross Margin	91.63%	52W Low	107.33%	ATR (14)	0.65
Dividend Ex-Date	-	Current Ratio	6.36	EPS Y/Y TTM	50.50%	Oper. Margin	-17.14%	RSI (14)	84.93	Volatility	0.08% 0.27%
Employees	860	Debt/Eq	0.01	Sales Y/Y TTM	46.62%	Profit Margin	-10.97%	Recom	2.64	Target Price	132.00
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	46.36%	Payout	-	Rel Volume	0.60	Prev Close	131.25
Sales Surprise	3.01%	EPS Surprise	-117.39%	Sales Q/Q	50.81%	Earnings	Feb 21 BMO	Avg Volume	3.07M	Price	131.24
SMA20	1.23%	SMA50	8.20%	SMA200	48.83%	Trades		Volume	1,189,310	Change	-0.01%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-24-25	Downgrade	Mizuho	Outperform → Neutral	$140 → $132
Jan-31-25	Downgrade	Canaccord Genuity	Buy → Hold	$119 → $132
Sep-06-24	Upgrade	Piper Sandler	Neutral → Overweight	$68 → $92
Jan-03-24	Initiated	Robert W. Baird	Outperform	$83
Dec-11-23	Initiated	TD Cowen	Outperform	$75
Apr-20-23	Initiated	Morgan Stanley	Overweight	$80
Aug-22-22	Downgrade	Goldman	Buy → Neutral	$64 → $49
Jul-07-22	Initiated	Mizuho	Buy	$74
Jun-14-22	Initiated	UBS	Buy	$75
Apr-22-22	Initiated	Piper Sandler	Neutral	$59
Feb-16-22	Initiated	Goldman	Buy	$64
Sep-23-21	Initiated	Needham	Buy	$55
Dec-15-20	Initiated	BofA Securities	Buy	$40
Dec-10-20	Initiated	Goldman	Buy	$38
Feb-20-20	Initiated	Evercore ISI	Outperform
Jan-31-20	Downgrade	JP Morgan	Overweight → Neutral	$26
Dec-24-19	Reiterated	Canaccord Genuity	Buy	$29 → $65
Aug-12-19	Initiated	Jefferies	Buy	$16
Feb-26-18	Initiated	JP Morgan	Overweight
Feb-08-18	Initiated	RBC Capital Mkts	Outperform	$33

Show Previous Ratings

Mar-01-25 03:28PM	Intra-Cellular Therapies, Inc. (ITCI): Among the Best Psychedelic Stocks to Buy in 2025 (Insider Monkey)
Feb-21-25 09:10AM	Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:17AM	Intra-Cellular: Q4 Earnings Snapshot (Associated Press Finance)
08:00AM	Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results (GlobeNewswire)
Feb-05-25 09:59AM	Steady M&A Deals to Begin 2025, Disappointing IPOs So Far (GuruFocus.com)
03:27AM	Loading…
Jan-26-25 03:27AM	Why Intra-Cellular Therapies (ITCI) Is Skyrocketing Now (Insider Monkey)
Jan-24-25 06:28AM	Why Intra-Cellular Therapies, Inc. (ITCI) Is Skyrocketing Now (Insider Monkey)
Jan-23-25 03:40PM	Biotech Venture Investors Optimistic, But Uncertainties Persist (The Wall Street Journal)
02:02AM	Johnson & Johnson (JNJ) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ... (GuruFocus.com)
Jan-22-25 12:03PM	Downside risk from talc lawsuit, Stelara generic competition is 'manageable': JNJ CFO Joe Wolk (Yahoo Finance)
10:22AM	Johnson & Johnson stock down despite beat on full-year, Q4 2024 earnings (Yahoo Finance)
Jan-20-25 09:54AM	What Analysts Think of Johnson & Johnson Stock Ahead of Earnings (Investopedia)
Jan-19-25 01:00PM	Why Intra-Cellular Therapies, Inc. (ITCI) Dominated Last Week's Rally (Insider Monkey)
Jan-18-25 09:42PM	Jim Cramer on Intra-Cellular Therapies, Inc. (ITCI): 'Intra-Cellular Had Something' (Insider Monkey)
Jan-15-25 11:00AM	J&J's AAA Rating in Jeopardy as Acquisition Sparks Debt Concerns (GuruFocus.com)
10:16AM	Loading…
10:16AM	J&Js Top Rating at Risk Because of Intra-Cellular Deal (Bloomberg)
Jan-14-25 12:13PM	J&J to leverage Intra-Cellular Therapies neurology portfolio (Pharmaceutical Technology)
09:53AM	Why Intra-Cellular (ITCI) Led the Monday Upsurge? (Insider Monkey)
08:56AM	ITCI Poised for Turnaround Amid Rising Mental Health Concerns (GuruFocus.com)
06:58AM	Intra-Cellular (ITCI) Moves 34.1% Higher: Will This Strength Last? (Zacks)
05:51AM	ITCI Stock Surges 34% as J&J Reveals $14.6 Billion Acquisition Plan (GuruFocus.com)
Jan-13-25 04:47PM	JPMorgan Healthcare Conference: AI, billion-dollar deals (Yahoo Finance Video) +34.07%
04:24PM	These Stocks Are Moving the Most Today: Micron, Intra-Cellular Therapies, and More (Barrons.com)
04:19PM	J&J Announces A Splashy $14.6 Billion Deal, While Lilly Tacks On A Cancer Drug (Investor's Business Daily)
03:13PM	Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal (The Wall Street Journal)
10:30AM	J&J buys Intra-Cellular in $14.6 billion deal, delving further into central nervous system disorders (Associated Press Finance)
10:15AM	Intra-Cellular Therapies Soars 32% With Johnson & Johnson's $14.6B Acquisition (GuruFocus.com)
10:14AM	Johnson & Johnson Makes Biopharmaceutical Splash with $14.6B Intra-Cellular Deal (Design & Development Today)
09:09AM	Johnson & Johnson Buys Intra-Cellular Therapeutics In A Whopping $14.6 Billion Deal (Investor's Business Daily)
08:49AM	Intra-Cellular Therapies Stock Pops as Johnson & Johnson Buys Firm for $14.6B (Investopedia)
08:49AM	Loading…
08:49AM	Intra-Cellular Therapies Stock Pops as Johnson and Johnson Buys Firm for $14.6B (Investopedia)
07:45AM	Update: Johnson & Johnson acquires Intra-Cellular Therapies (Pharmaceutical Technology)
07:45AM	Johnson & Johnson in talks to acquire Intra-Cellular Therapies (Pharmaceutical Technology)
06:37AM	J&J doubles down on neurological drugs with $14.6 billion Intra-Cellular deal (Reuters)
06:32AM	Johnson and Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc. (GlobeNewswire)
06:32AM	Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc. (GlobeNewswire)
05:34AM	Intra-Cellular (ITCI) Surges 14.9%: Is This an Indication of Further Gains? (Zacks)
02:34AM	J&J to buy psychiatric drug developer Intra-Cellular for $14.6B (BioPharma Dive)
Jan-11-25 10:40AM	RBC buyers of Intra-Cellular after more favorable-than-expected settlement (TipRanks)
Jan-10-25 01:11PM	Intra-Cellular Therapies Stock Soars 19% After Securing Major Patent Victory Over Sandoz (GuruFocus.com) +14.91%
06:30AM	Intra-Cellular Therapies Settles CAPLYTA (lumateperone) Patent Litigation with Sandoz (GlobeNewswire)
Jan-06-25 08:00AM	Intra-Cellular Therapies to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-11-24 08:00AM	Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College of Neuropsychopharmacology Annual Meeting (GlobeNewswire)
Dec-03-24 07:30AM	Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy (GlobeNewswire)
Nov-29-24 11:31AM	Why Is Intra-Cellular (ITCI) Up 2.2% Since Last Earnings Report? (Zacks)
Nov-27-24 06:00AM	How Intra-Cellular surprised Wall Street by breaking character (BioPharma Dive)
Nov-19-24 08:00AM	Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Nov-07-24 08:00AM	Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress (GlobeNewswire)
Nov-06-24 01:07PM	Intra-Cellular bolsters Caplyta data with another Phase III win (Pharmaceutical Technology)
Nov-05-24 07:00AM	Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia (GlobeNewswire)
Oct-31-24 03:07AM	Intra-Cellular Therapies Inc (ITCI) Q3 2024 Earnings Call Highlights: Robust Sales Growth and ... (GuruFocus.com)
Oct-30-24 08:40AM	Intra-Cellular Therapies (ITCI) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +11.36%
07:40AM	Intra-Cellular: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance (GlobeNewswire)
Oct-29-24 09:05AM	What To Expect From Intra-Cellular Therapies Inc (ITCI) Q3 2024 Earnings (GuruFocus.com)
Oct-23-24 10:01AM	Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-17-24 08:00AM	Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast (GlobeNewswire)
Oct-13-24 07:23PM	Intra-Cellular Therapies, Inc. (ITCI): Among the Most Promising Mid-Cap Stocks According to Hedge Funds (Insider Monkey)
Oct-10-24 03:05PM	JPMorgan Chase & Co's Strategic Acquisition of Shares in Intra-Cellular Therapies Inc (GuruFocus.com)
Sep-23-24 08:00AM	Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress (GlobeNewswire)
Sep-06-24 11:31AM	Why Is Intra-Cellular (ITCI) Down 2.7% Since Last Earnings Report? (Zacks)
Sep-05-24 01:12AM	Intra-Cellular Therapies, Inc. (ITCI): Among the Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Sep-02-24 06:05PM	10 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-28-24 08:00AM	Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 11:06AM	Biotech Stock Pulls Back After Earnings Report; Profits On The Horizon (Investor's Business Daily)
09:54AM	Intra-Cellular (ITCI) Q2 Loss Narrower Than Expected, Sales Beat (Zacks)
08:00AM	Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference (GlobeNewswire)
Aug-07-24 04:14PM	Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains' (Investor's Business Daily) -5.81%
08:45AM	Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:41AM	Intra-Cellular: Q2 Earnings Snapshot (Associated Press Finance)
07:40AM	Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial Officer (GlobeNewswire)
07:30AM	Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance (GlobeNewswire)
Jul-31-24 10:01AM	Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Jul-24-24 08:00AM	Intra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and Webcast (GlobeNewswire)
Jul-09-24 09:55AM	Wall Street Analysts See a 30.14% Upside in Intra-Cellular (ITCI): Can the Stock Really Move This High? (Zacks)
Jun-24-24 09:52AM	Intra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe (Zacks)
Jun-20-24 02:37PM	Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87 (Investor's Business Daily)
Jun-19-24 10:27AM	Intra-Cellular (ITCI) Up as Second Depression Study Meets Goals (Zacks)
06:27AM	Intra-Cellular (ITCI) Soars 9.6%: Is Further Upside Left in the Stock? (Zacks)
Jun-18-24 04:22PM	Intra-Cellular Therapies Eyes $1.7 Billion Opportunity After Phase 3 Win (Investor's Business Daily) +9.60%
01:34PM	Intra-Cellular Therapies edges closer to FDA win for Caplyta in depression (Clinical Trials Arena)
07:30AM	Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder (GlobeNewswire)
07:30AM	Intra-Cellular depression drug succeeds in second late-stage study (BioPharma Dive)
Jun-10-24 08:00AM	Intra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare Conference (GlobeNewswire)
Jun-06-24 11:31AM	Why Is Intra-Cellular (ITCI) Up 1.2% Since Last Earnings Report? (Zacks)
May-30-24 06:00AM	The Secret Stock Stash: 3 Overlooked Picks That Belong in Every Portfolio (InvestorPlace)
May-29-24 08:00AM	Intra-Cellular Therapies to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-27-24 06:34PM	Hedge Funds Like Intra-Cellular Therapies (NASDAQ:ITCI) (Insider Monkey)
06:13PM	7 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
May-23-24 08:00AM	Intra-Cellular Therapies Highlights Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting (GlobeNewswire)
May-08-24 03:44PM	Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q1 2024 Earnings Call Transcript (Insider Monkey) -5.91%
11:43AM	Intra-Cellular (ITCI) Q1 Earnings and Sales Beat Estimates (Zacks)
08:00AM	Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
03:13AM	Intra-Cellular Therapies Inc (ITCI) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue ... (GuruFocus.com)
May-07-24 09:18AM	Sector Update: Health Care Stocks Steady Pre-Bell Tuesday (MT Newswires)
09:12AM	Intra-Cellular Therapies Surpasses Q1 Revenue Estimates with Strong CAPLYTA Sales (GuruFocus.com)
08:40AM	Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:16AM	Intra-Cellular Therapies' Q1 Net Loss Narrows, Net Total Revenue Rises (MT Newswires)
07:37AM	Intra-Cellular: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	Intra-Cellular Therapies Reports First Quarter 2024 Financial Results (GlobeNewswire)

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm's lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in Bedminster, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MARCUS JOEL S	Director	Feb 24 '25	Option Exercise	63.79	7,009	447,104	48,238	Feb 26 06:01 PM
Mates Sharon	Chairman and CEO	Dec 05 '24	Option Exercise	12.73	51,697	658,103	1,122,026	Dec 06 06:01 PM
Mates Sharon	Chairman and CEO	Dec 04 '24	Option Exercise	12.73	51,000	649,230	1,121,329	Dec 06 06:01 PM
Mates Sharon	Chairman and CEO	Dec 04 '24	Sale	85.80	51,000	4,375,659	1,070,329	Dec 06 06:01 PM
Mates Sharon	Chairman and CEO	Dec 05 '24	Sale	84.08	51,697	4,346,842	1,070,329	Dec 06 06:01 PM
Mates Sharon	Officer	Dec 05 '24	Proposed Sale	84.02	51,697	4,343,616		Dec 05 04:27 PM
Mates Sharon	Officer	Dec 04 '24	Proposed Sale	85.73	51,000	4,372,478		Dec 04 04:18 PM
Halstead Michael	President	Nov 13 '24	Option Exercise	36.89	18,714	690,359	18,714	Nov 14 06:01 PM
Halstead Michael	President	Nov 12 '24	Option Exercise	23.94	22,869	547,484	22,869	Nov 14 06:01 PM
Halstead Michael	President	Nov 12 '24	Sale	89.12	22,869	2,038,079	0	Nov 14 06:01 PM
Halstead Michael	President	Nov 13 '24	Sale	88.38	18,714	1,654,021	0	Nov 14 06:01 PM
Halstead Michael	Officer	Nov 12 '24	Proposed Sale	89.08	41,583	3,704,223		Nov 12 04:28 PM
ALEXANDRIA VENTURE INVESTMENTS	Director	Sep 06 '24	Proposed Sale	73.17	25,000	1,829,178		Sep 06 05:43 PM
Mates Sharon	Chairman and CEO	Aug 29 '24	Option Exercise	12.73	35,604	453,239	1,105,933	Aug 30 06:01 PM
Mates Sharon	Chairman and CEO	Aug 30 '24	Option Exercise	12.73	34,396	437,861	1,104,725	Aug 30 06:01 PM
Mates Sharon	Chairman and CEO	Aug 29 '24	Sale	72.57	35,604	2,583,884	1,070,329	Aug 30 06:01 PM
Mates Sharon	Chairman and CEO	Aug 30 '24	Sale	72.84	34,396	2,505,351	1,070,329	Aug 30 06:01 PM
Mates Sharon	Officer	Aug 30 '24	Proposed Sale	72.78	34,396	2,503,218		Aug 30 04:06 PM
Mates Sharon	Officer	Aug 29 '24	Proposed Sale	72.51	35,604	2,581,677		Aug 29 04:34 PM
Mates Sharon	Chairman and CEO	Aug 27 '24	Option Exercise	17.57	40,513	711,813	1,110,842	Aug 28 06:00 PM
Mates Sharon	Chairman and CEO	Aug 28 '24	Option Exercise	17.57	32,699	574,521	1,103,028	Aug 28 06:00 PM
Mates Sharon	Chairman and CEO	Aug 26 '24	Option Exercise	17.57	22,713	399,067	1,093,042	Aug 28 06:00 PM
Mates Sharon	Chairman and CEO	Aug 27 '24	Sale	73.58	40,513	2,981,056	1,070,329	Aug 28 06:00 PM
Mates Sharon	Chairman and CEO	Aug 28 '24	Sale	72.75	32,699	2,378,801	1,070,329	Aug 28 06:00 PM
Mates Sharon	Chairman and CEO	Aug 26 '24	Sale	74.59	22,713	1,694,229	1,070,329	Aug 28 06:00 PM
Mates Sharon	Officer	Aug 28 '24	Proposed Sale	72.69	32,699	2,376,774		Aug 28 04:34 PM
Mates Sharon	Officer	Aug 27 '24	Proposed Sale	73.52	40,513	2,978,542		Aug 27 04:22 PM
Mates Sharon	Officer	Aug 26 '24	Proposed Sale	74.53	22,713	1,692,819		Aug 26 04:36 PM
Mates Sharon	Chairman and CEO	Aug 21 '24	Option Exercise	17.57	53,013	931,438	1,123,342	Aug 23 06:00 PM
Mates Sharon	Chairman and CEO	Aug 22 '24	Option Exercise	17.57	39,380	691,907	1,109,709	Aug 23 06:00 PM
Mates Sharon	Chairman and CEO	Aug 23 '24	Option Exercise	17.57	28,680	503,908	1,099,009	Aug 23 06:00 PM
Mates Sharon	Chairman and CEO	Aug 21 '24	Sale	75.65	53,013	4,010,501	1,070,329	Aug 23 06:00 PM
Mates Sharon	Chairman and CEO	Aug 22 '24	Sale	74.68	39,380	2,940,802	1,070,329	Aug 23 06:00 PM
Mates Sharon	Chairman and CEO	Aug 23 '24	Sale	74.46	28,680	2,135,435	1,070,329	Aug 23 06:00 PM
Mates Sharon	Officer	Aug 23 '24	Proposed Sale	74.40	28,680	2,133,656		Aug 23 04:14 PM
Mates Sharon	Officer	Aug 22 '24	Proposed Sale	74.62	39,380	2,938,358		Aug 22 04:09 PM
Mates Sharon	Officer	Aug 21 '24	Proposed Sale	75.59	53,013	4,007,208		Aug 21 04:25 PM
Neumann Mark	EVP, Chief Commercial Officer	Aug 16 '24	Option Exercise	36.89	18,714	690,359	48,414	Aug 20 06:03 PM
Neumann Mark	EVP, Chief Commercial Officer	Aug 16 '24	Sale	75.08	18,714	1,405,047	29,700	Aug 20 06:03 PM
Neumann Mark	Officer	Aug 16 '24	Proposed Sale	75.02	18,714	1,403,972		Aug 16 04:04 PM
RIGGS RORY B	Director	Jun 24 '24	Option Exercise	16.86	20,000	337,200	121,062	Jun 25 06:04 PM
RIGGS RORY B	Director	Jun 24 '24	Sale	75.57	4,462	337,193	116,600	Jun 25 06:04 PM
VAN NOSTRAND ROBERT L	Director	Jun 18 '24	Option Exercise	16.86	20,000	337,200	29,690	Jun 21 06:00 PM
VAN NOSTRAND ROBERT L	Director	Jun 18 '24	Sale	75.91	20,000	1,518,199	9,690	Jun 21 06:00 PM
Mates Sharon	Chairman and CEO	Apr 24 '24	Option Exercise	17.26	20,020	345,618	1,070,329	Apr 25 05:08 PM
RIGGS RORY B	Director	Mar 20 '24	Option Exercise	18.56	20,000	371,200	99,235	Mar 22 04:12 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Intra-Cellular Therapies Inc

Upgrade your FINVIZ experience